Roivant Sciences Ltd.
Close on Nov 20, 2026Market cap $27.92BP/E –Yield –
Roivant Sciences Arbutus Biopharma Corp. (ABUS) by Quarter
Arbutus Biopharma Corp. (ABUS) — Collaboration & License Revenue ($M)
Roivant Sciences Arbutus Biopharma Corp. (ABUS): $0.30M in Q2 FY2026, down 43.4% from a year earlier. That is the lowest of the 20 quarters on record here.
Where the Q2 FY2026 figure comes from
Source: Arbutus Biopharma Corp. Form 10-Q (filed 2026-11-10) ↗
Reported in ABUS Form 10-K / 10-Q (XBRL).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up arbutus Biopharma Corp. (ABUS)
- Arbutus Biopharma Corp. (ABUS) — R&D Expense2.62 · Q2 FY2026
- Arbutus Biopharma Corp. (ABUS) — G&A Expense7.96 · Q2 FY2026
- Arbutus Biopharma Corp. (ABUS) — Net Income (Loss)59.1 · Q2 FY2026
- Arbutus Biopharma Corp. (ABUS) — Cash & Cash Equivalents264 · Q2 FY2026
- Arbutus Biopharma Corp. (ABUS) — Marketable Securities73.3 · Q2 FY2026
- Arbutus Biopharma Corp. (ABUS) — Common Shares Outstanding199 · Q2 FY2026
- Arbutus Biopharma Corp. (ABUS) — Antidilutive Securities8.24 · Q2 FY2026
Cite this data
StockData. (2026). Roivant Sciences Arbutus Biopharma Corp. (ABUS) ($M), quarterly Q1 FY2020–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/abus-rev-row
See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.
See a number that looks wrong?